Pfizergan Offers Warm Embrace For Pfizer’s Internal And Allergan’s External R&D
Pfizer R&D chief Mikael Dolsten and his counterpart at Allergan, David Nicholson, oversee very different research organizations, but in interviews at the J.P. Morgan Healthcare Conference the two heads of R&D insisted the chasm between their research models is not so vast.
You may also be interested in...
The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.
The start-up will secure $70m from Genentech, after closing a series B financing, while it moves its first CAR-T program into the clinic for ovarian cancer later this year.
Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.